Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER)

@inproceedings{Trenkwalder2011RotigotineEO,
  title={Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER)},
  author={Claudia Trenkwalder and Bryan Kies and Monika Rudzinska and Jennifer Fine and J{\'a}nos Nikl and Krystyna Honczarenko and P{\'e}ter Di{\'o}szeghy and Dennis W. Hill and Tim Anderson and Vilho V. Myllyla and Jan Kassubek and Malcolm J. Steiger and Marco Zucconi and Eduardo Tolosa and Werner Poewe and Erwin Surmann and John G Whitesides and Babak Boroojerdi and Kallol Ray Chaudhuri},
  booktitle={Movement disorders : official journal of the Movement Disorder Society},
  year={2011}
}
In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control were randomized 2:1 to receive rotigotine (2-16 mg/24 hr [n = 190]) or placebo (n = 97). Treatment was titrated to optimal dose over 1-8 weeks with subsequent dose maintenance for 4 weeks… CONTINUE READING